NCT02132689

Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism

Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism in Context of Pulmonary Hypertension, Right Heart Failure and Patient Functional Ability

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: University Hospital Ostrava · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Currently there is no clear guidance for the treatment of moderate risk of pulmonary embolism. The aim of the study is to compare two different therapeutic modalities - standard anticoagulation versus thrombolytic treatment followed by anticoagulation in standard regimen as stated in the pulmonary embolism guidelines.

Detailed description

Standard treatment of moderate risk pulmonary embolism constitutes of sole anticoagulation therapy. In case of troponin positivity and/or echocardiographic findings as i.e. thrombi in RV thrombolytic therapy should be considered. The aim of this trial is to compare the two treatment modalities in their ability to reduce/predict 12 month end-point: pulmonary hypertension, right ventricular failure, exercise capacity.

Conditions

• Pulmonary Embolism

Interventions

Type	Name	Description
DRUG	Actilyse (Thrombolytic therapy)
DRUG	Heparine (Standard anticoagulation therapy)

Timeline

• Start date: 2011-03-01
• Primary completion: 2015-05-01
• Completion: 2015-12-01
• First posted: 2014-05-07
• Last updated: 2018-03-19

Locations

2 sites across 1 country: Czechia